A Double-Blind, Randomized, Placebo-Controlled, Multiple, Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2011
At a glance
- Drugs OSI 754 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 14 Mar 2011 Last checked against ClinicalTrials.gov record.
- 14 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.